Comparative Pharmacology
Head-to-head clinical analysis: BENYLIN versus TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENYLIN versus TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE.
BENYLIN vs TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BENYLIN (diphenhydramine) is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, thereby alleviating allergic symptoms. It also crosses the blood-brain barrier and acts as a central nervous system depressant via inhibition of histamine and acetylcholine, producing sedative, antiemetic, and antitussive effects.
Triprolidine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
Oral: 10-20 mL (25-50 mg diphenhydramine) every 4-6 hours; maximum 100 mg per day.
1 tablet (triprolidine 2.5 mg/pseudoephedrine 60 mg) orally every 4 to 6 hours; maximum 4 tablets per 24 hours.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in adults; extended to 10-12 hours in hepatic impairment, increasing risk of accumulation.
Triprolidine: 3-5 hours (terminal). Pseudoephedrine: 5-8 hours (terminal, pH-dependent; urine pH 8: ~13 hours, pH 5: ~3 hours). Clinical: normal renal function.
Renal: ~80% as unchanged drug and glucuronide conjugates; fecal/biliary: ~20%.
Triprolidine: ~80% renal (mostly metabolites, <5% unchanged). Pseudoephedrine: ~70-90% renal (43-96% unchanged, depends on urine pH; acidic urine increases elimination, alkaline decreases). Biliary/fecal: negligible for both.
Category C
Category A/B
Antihistamine
Antihistamine